Avenacy Launches Eptifibatide Injection in the U.S. Market

Tuesday, April 30, 2024

Avenacy, a pharmaceutical company specializing in critical injectable medications, has introduced Eptifibatide for Injection in the United States. This medication, approved by the U.S. Food and Drug Administration, serves as a generic equivalent for Integrilin® for Injection (Eptifibatide). It is indicated for treating acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI).

Eptifibatide for Injection is available in a 75 mg/100 mL single-dose vial and features unique packaging and labeling to ensure accurate medication selection, aligning with Avenacy's commitment to patient safety and efficient care.

Shipments of Eptifibatide for Injection to wholesale partners will begin this week. Avenacy collaborates with a global network of development and FDA-approved cGMP-certified contract manufacturing partners.

Eptifibatide for Injection generated U.S. sales of approximately $8.3 million in the twelve months ending in June 2023.

Approved Uses:

1. Acute Coronary Syndrome (ACS): Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction in patients with ACS (unstable angina/non-ST-elevation myocardial infarction), including patients managed medically and those undergoing percutaneous coronary intervention.
    
2. Percutaneous Coronary Intervention (PCI): Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting.
   
    

Source: businesswire.com